Shenzhen Alpha Molecular Technology

Shenzhen Alpha Molecular Technology (AlphaMol) is a biotechnology company specializing in AI-driven drug discovery with a primary focus on G protein-coupled receptors (GPCRs). The company integrates advanced artificial intelligence, physics-based molecular simulations, and high-throughput experimental validation to accelerate the development of novel small molecule therapeutics. Founded in 2020 by experts in computational biology and medicinal chemistry, Alpha Molecular aims to address challenging drug targets in therapeutic areas such as metabolic disorders, oncology, and central nervous system diseases. Their proprietary platform combines deep learning with structural biology to optimize lead compounds and improve the success rate of drug development. The firm has secured significant venture capital funding from prominent investors to advance its internal pipeline and collaborative projects.